Michael Shankman - Oct 1, 2024 Form 3 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Chief Financial Officer
Signature
/Michael Shankman/
Stock symbol
LEXX
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
3
Date filed
10/2/2024, 03:45 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LEXX Stock Options Oct 1, 2024 Common Shares 50K $3.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20,000 options are exercisable on February 28, 2025, thereafter an additional 15,000 options will be exercisable on August 31, 2025 and the remaining 15,000 options will be exercisable on August 31, 2026